Americans for Safe Access

OCTOBER 17, 2017

On October 15, 2017, the Washington Post and 60 Minutes released a scathing report on the pharmaceutical industry’s influence of the Drug Enforcement Administration (DEA).

Policy 113

Policy DEA Pharmaceutical Legislation 113

NORML

MARCH 1, 2019

In August 2016, the US Drug Enforcement Administration announced in the US Federal Register that the agency was “adopting a new policy that is designed to increase the number of entities registered under the Controlled Substances Act to grow (manufacture) marijuana to supply legitimate researchers in the United States.”

DEA 168

DEA Research and Development Clinical Trials Marijuana 168

Veriheal

JANUARY 16, 2024

This occasion marks the first time that a federal agency has recommended rescheduling cannabis, and this could be the push the Drug Enforcement Administration (DEA) needs to finally make it happen. It may also result in federal legalization and easier access in states that have yet to legalize medicinal or recreational marijuana.

DEA 119

DEA Medicine Cannabis Legalization 119

WeedAdvisor

AUGUST 28, 2019

Despite a 90-day deadline for review, the DEA ignored this cut-off and simply sat on the applications for three years. This likely would have been longer, but the DEA had not anticipated a legal threat to force some action. Given the DEA’s stonewalling, forcing their hand is a notable achievement. Dozens of Applications”. .

DEA 61

DEA Marijuana History THC 61

Cannabis Law Report

FEBRUARY 10, 2022

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). By Allison Campbell.

DEA 52

DEA Clinical Trials Policy Research and Development 52

Cannabis Law Report

JUNE 16, 2022

NORML’s Political Director Morgan Fox added: “The fact that these interdiction efforts are growing — at great cost to the taxpayer — despite increasing momentum for legalization is a testament to the failure of federal prohibition and unnecessarily burdensome state regulatory policies.

DEA 52

DEA Marijuana Programs Data 52

Cannabis Law Report

OCTOBER 4, 2021

Accordingly, it cannot be prescribed by a physician and it is not legally accessible to those who might benefit from it as a therapeutic treatment. Access Pursuant to the Oregon Psilocybin Services Act. The shelter provided by this approach depends on the policy of the U.S. Source: [link].

Therapy 52

Therapy Patients Law Clinical Trials 52

Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. Lastly, the guide lays out the complex DEA registration process researchers much navigate to gain access to plants like psilocybin.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

JULY 7, 2021

Pennington, who focuses on federal appeals and regulatory issues, is co-counsel on several high-profile cases against the DEA regarding cannabis research, hemp, and psychedelics. Circuit), a pending petition for review of DEA’s August 2020 Interim Final Rule purportedly implementing the 2018 Farm Bill’s amendments to the CSA.

DEA 111

DEA Hemp Cultivation Advocacy 111

SMPL

AUGUST 14, 2019

The American Bar Association (ABA) adopted a resolution on Monday that calls on Congress to allow states to set their own marijuana policies and recommends rescheduling or descheduling cannabis under federal law. One area that could be quickly improved is in the sourcing of research-grade marijuana.

Policy 40

Policy Research and Development Marijuana DEA 40

Veriheal

SEPTEMBER 13, 2022

It also may be more convenient to grow cannabis at home if a consumer lives in a rural area or in a state that only has a limited number of accessible dispensaries. Consumers are getting fed up with only having access to the same limited set of genetics in the dispensary. Homegrown cannabis gives all the power to the consumer.

Cultivation 109

Cultivation Data DEA Dispensary 109

Veriheal

NOVEMBER 6, 2023

Despite this massive shift in cannabis policy, however, a few states are still dragging their feet on cannabis legalization. The Act aimed to provide patients access to smokable flower for 15 medical conditions. This progressive legislation, once implemented, means a brand new slew of patients will have access to cannabis medicine.

Legalization 117

Legalization Recreational THC CBD 117

Cannabis Law Report

NOVEMBER 4, 2021

Should President Biden wish to acknowledge the political, economic, and moral realities surrounding cannabis policy, and fulfill the promises he made on the campaign trail, this report lays out a clear roadmap for how to do so.”. We’re beyond that.”. The FDA Director role continues to be unfilled.

DEA 52

DEA Marijuana Decriminalization Data 52

Veriheal

NOVEMBER 11, 2023

According to the United States Drug Enforcement Administration (DEA), Schedule One drugs are “drugs with no currently accepted medical use and a high potential for abuse.” Nonetheless, with the increasing legalization of medical cannabis, many veterans and interest groups have asked the government to change its policies.

Law 62

Law Chronic Pain Conditions Legislation 62

Cannabis Law Report

MAY 29, 2022

8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. DEA and the Controlled Substances Act. In addition to the arduous FDA approval process, potential psychedelic therapies would also require complying with requirements from the Drug Enforcement Administration (DEA). Times (Nov.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Canna Law Blog

JULY 14, 2023

You can access the letters here. But, there’s a huge controversy about whether it can be controlled, with agencies like the DEA saying it is. FTC Policy Statement on Deception, 103 F.T.C. For now, stay tuned to the Canna Law Blog for more updates on FDA and FTC cannabinoid policies and delta-8 products. 174, 176 n.9

Packaging 74

Packaging Food Edibles THC 74

Burns Levinson (Cannabusiness advisory)

OCTOBER 3, 2018

This marks the first time in history that the DEA has removed any type of cannabis from Schedule I, and clears the way for the sale of the first non-synthetic, cannabis-derived medicine to win federal approval. According to the DEA order, because the drug was recently approved by the FDA, it is now considered to have an accepted medical use.

CBD 40

CBD DEA Epilepsy Pharmaceutical 40

Cannabis Law Report

AUGUST 12, 2022

Drug policy topics have become a consistent feature of the Austin-based event in recent years as more states have legalized cannabis and moved to reform laws around psychedelics like psilocybin locally and at the state level. The panel would center on the evolution of cannabis policy in the U.S.,

Research and Development 52

Research and Development Events Topical Policy 52

Cannabis Law Report

JUNE 15, 2021

. – Today, ahead of the 50th anniversary—on June 17—of when President Richard Nixon declared the “war on drugs,” Representatives Bonnie Watson Coleman (D-NJ) and Cori Bush (D-MO) unveiled the Drug Policy Reform Act (DPRA), alongside the Drug Policy Alliance, which has been a strategic partner on the development of the legislation.

Decriminalization 78

Decriminalization Policy Research and Development Data 78

PrestoDoctor

JULY 16, 2019

Today, groups with a decade or less of experience advance policy and conversations alongside the veteran alliances of the movement. NORML acts as a resource for media on cannabis, as well as informs lawmakers, lobbies and other top officials regarding policy. The Drug Policy Alliance (DPA). The Drug Policy Alliance (DPA).

Policy 40

Policy DEA Access Media 40

PrestoDoctor

JULY 16, 2019

Today, groups with a decade or less of experience advance policy and conversations alongside the veteran alliances of the movement. NORML acts as a resource for media on cannabis, as well as informs lawmakers, lobbies and other top officials regarding policy. The Drug Policy Alliance (DPA). The Drug Policy Alliance (DPA).

Policy 40

Policy DEA Access Media 40

Veriheal

AUGUST 24, 2022

This campaign was backed by New Approach PAC, a nationwide political organization that is focused on supporting progressive reform surrounding cannabis and criminal justice policies. So much, in fact, that it actually gained the attention of the DEA , which recently called for an increase in psychedelic production for research purposes.

Legalization 109

Legalization Decriminalization Medicine Research and Development 109

Veriheal

DECEMBER 27, 2022

Researchers have taken a big step in understanding the connection between using psychedelics and feeling connected to nature in a study published in the journal Drug Science, Policy, and Law on Oct. Study findings indicated that those who had previously taken LSD and psilocybin reported a greater sense of “nature relatedness.”

Research and Development 101

Research and Development Therapy Consumption DEA 101

Cannabis Law Report

JULY 23, 2021

Drug Enforcement Agency (DEA) to the Alcohol and Tobacco Tax and Trade Bureau (TTB), the Bureau of Alcohol Tobacco Firearms and Explosives (ATF). It would transfer primary agency jurisdiction over cannabis from the DEA to the FDA, TTB, and ATF. If implemented, regulatory responsibility of cannabis would be transferred from the U.S.

Research and Development 105

Research and Development DEA Programs State Laws 105

CannaMD

SEPTEMBER 15, 2020

MORE DETAILS: On June 16, 2014, Florida became the 22nd state to legalize (at least partial) access to medical marijuana when Governor Rick Scott signed the Compassionate Medical Cannabis Act of 2014. To learn more about telehealth appointments and CannaMD ‘s COVID-19 safety measures, see: Coronavirus Policies. Law enforcement.

Law 126

Law Marijuana Patients Treatment 126

NORML

APRIL 8, 2020

As a result, the DEA has been encouraged for over a decade to expand the pool of federally licensed cannabis producers — a move that the agency has largely resisted. In 2016, the agency appeared to reconsider its longstanding policy, and publicly stated for the first time that it would consider additional applicants.

Cultivation 351

Cultivation DEA Clinical Trials Marijuana 351

Cannabis Law Report

JANUARY 13, 2022

In The Weeds welcomes the new year, as well as a number of new cannabis laws and policies taking effect around the country in 2022. 1, Louisiana’s medical cannabis program allows patients to access smokable whole-plant flower marijuana. McGuireWoods LLP. Newsworthy Highlights. Happy 2022! Montana: As of Jan. Louisiana: As of Jan.

Dispensary 52

Dispensary Law Concentrates DEA 52

Canna Law Blog

JANUARY 11, 2022

The issue of enforcement or compliance is probably the biggest one most states face at the policy level. The thought process goes that three things will reduce the illicit market: (1) federal and statewide legalization, (2) incentives to access the legal market, and (3) putting compliance ahead of enforcement.

Compliance 77

Compliance Compliance State Laws DEA 77

SpeedWeed

AUGUST 19, 2021

In recent months, a synthetic compound derived from hemp called THC-O acetate—often referred to simply as THC-O (pronounced “THC oh”)—has quickly gained popularity among Americans who don’t have access to legal cannabis. . THC-O products are increasingly popular in states where consumers don’t have access to legal cannabis.

THC 52

THC Hemp Extraction Vaping 52

Cannabis Law Report

FEBRUARY 28, 2022

Importantly, control of psychedelics by a small number of companies may stifle innovation and reduce access to these therapies. 1669, 1670 (2021) (arguing that patents on psychedelics may limit research, innovation, and public access). Glenn Cohen, Psychedelic Therapy: A Roadmap for Wider Acceptance and Utilization , 27 NATURE MED.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

SpeedWeed

MARCH 18, 2021

Given the topical nature of the current trial and its relevance for public policy on medical cannabis, participants might have been biased to report positive effects regardless of condition. Wasn’t the DEA going to let others grow research-grade cannabis? It tested at only 9% THC. Research quality” cannabis sparked earlier controversy.

Clinical Trials 40

Clinical Trials THC Strains Cannabis 40

Americans for Safe Access

AUGUST 31, 2023

Their findings were sent to the Drug Enforcement Administration (DEA) who will be performing the final review for the Department of Justice (DOJ) in response to President Biden’s request in October 2022 for HHS and DOJ to look into the scheduling of cannabis.

Policy 255

Policy DEA Food Cannabis 255

Canna Law Blog

NOVEMBER 6, 2021

Despite overwhelming evidence that psilocybin is misclassified, this barrier restricts research, stifles competition and innovation, and inhibits access. But only if it is made affordable and accessible. That power is typically delegated to the DEA. Psilocybin’s federal status as a Schedule I controlled substance is to blame.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

Cannabis Law Report

JULY 1, 2021

The Project on Psychedelics Law and Regulation at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School will advance evidence-based psychedelics law and policy. Mason Marks: The project’s goal is to promote safety, innovation, equity, and accessibility in emerging psychedelics industries.

Law 105

Law Research and Development Therapy DEA 105

Veriheal

AUGUST 19, 2022

But times are changing, and leaders are now calling for revamped policies on psilocybin, hemp, and cannabis research for varying reasons. ” Cannabis Research Should Be Based on Real, Accessible Products. The DEA stated that they were starting the process of approving additional cannabis cultivators back in 2016.

Hemp 52

Hemp DEA Access Cultivation 52

Cannabis Law Report

SEPTEMBER 23, 2019

During the 20 th century, law enforcement and public policy activities have undermined opportunities for scientific exploration. Relevant AAFP Policy. Family physicians have a vested interest in policies that advance and protect the health of their patients and the public. Marijuana Possession for Personal Use. Call to Action.

Cannabinoids 40

Cannabinoids Marijuana Research and Development Access 40

Veriheal

DECEMBER 21, 2022

The Drug Enforcement Administration (DEA) is now mandated to approve applications to be manufacturers of marijuana-derived, FDA-approved drugs under the bill. While both options seem better than the current situation, they could actually make it more difficult to access. The law gives the U.S. Descheduling Cannabis.

Clinical Trials 98

Clinical Trials Marijuana Decriminalization History 98